Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-023-01103-4
Purpose of Review To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 American College of Cardiology (ACC) conference. Recent findings The CLEAR outcomes randomized control...
Summary: The late-breaking clinical science presented at the 2023 conference of the ACC paves the way for an evidence-based alternative to statin therapy and provides data on several common clinical scenarios encountered in daily practice.
Share
Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up
Source : https://academic.oup.com/ehjopen/article/3/2/oead035/7107070?login=false
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein like particle containing apolipoprotein B covalently linked to a carbohydrate-rich protein termed apolipoprotein(a) [apo(a)]. Mechanistic and epidemiologic studies indicate that Lp(a) levels are significantly...
Conclusion: This study demonstrated that Lp(a) levels in individuals with acute MI are significantly higher six months after the initial event. Therefore, a single measurement of Lp(a) in the peri-infarction setting is not sufficient to predict the Lp(a)-associated CAD risk in the post-infarction period.
Share
Conclusions and relevance: In this cohort study of Asian patients with breast cancer, statin use was associated with a reduced risk of cancer-associated death rather than cardiovascular death. Our findings provide evidence to support the use of statins in patients with breast cancer; however, randomized studies are necessary.
Share
Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3
Source : https://www.sciencedirect.com/science/article/abs/pii/S0735109723045229?via=ihub
The availability of , , and (FH). However, a great number of individuals with FH do not achieve guideline-recommended low-density lipoprotein (LDL) cholesterol levels despite maximal lipid-lowering therapy. Novel therapies...
Conclusions/Relevance: Conduction of cardiovascular outcomes clinical trials in patients with FH can be challenging because of difficulty in recruitment and long periods of follow-up. In the future, the use of validated surrogate measures of atherosclerosis may allow for clinical trials with fewer study participants and shorter duration,...
Share
LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37080805/
In routine practice, only a minority of women and men with FH achieved their LDL-C treatment target. Extra efforts have to be made to provide FH patients with reliable information...
Conclusions: In routine practice, only a minority of women and men with FH achieved their LDL-C treatment target. Extra efforts have to be made to provide FH patients with reliable information on the safety of statins and their long-term effects on CVD risk reduction. If statin treatment is insufficient, alternative lipid lowering...
Share